Validated using a knockout cell line

Anti-INPPL1 / SHIP-2 antibody [EPR10955] (ab166916)


  • Product name
    Anti-INPPL1 / SHIP-2 antibody [EPR10955]
    See all INPPL1 / SHIP-2 primary antibodies
  • Description
    Rabbit monoclonal [EPR10955] to INPPL1 / SHIP-2
  • Host species
  • Tested applications
    Suitable for: WB, IHC-P, ICC/IFmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human INPPL1/ SHIP-2 aa 950-1050. The exact sequence is proprietary.

  • Positive control
    • K562, HeLa cell lysate; Human heart tissue; Human kidney tissue; HeLa cells
  • General notes



    Previously labelled as INPPL1. 

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab166916 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 139 kDa.
IHC-P 1/100 - 1/250.
ICC/IF 1/100 - 1/250.
  • Application notes
    Is unsuitable for Flow Cyt or IP.
  • Target

    • Function
      Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Plays a central role in regulation of PI3K-dependent insulin signaling, although the precise molecular mechanisms and signaling pathways remain unclear. While overexpression reduces both insulin-stimulated MAP kinase and Akt activation, its absence does not affect insulin signaling or GLUT4 trafficking. Confers resistance to dietary obesity. May act by regulating AKT2, but not AKT1, phosphorylation at the plasma membrane. Part of a signaling pathway that regulates actin cytoskeleton remodeling. Required for the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation. Participates in regulation of cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling. Regulates cell adhesion and cell spreading. Required for HGF-mediated lamellipodium formation, cell scattering and spreading. Acts as a negative regulator of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1 activation. Acts as a regulator of neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required to form an initial protrusive pattern, and later, maintain proper neurite outgrowth. Acts as a negative regulator of the FC-gamma-RIIA receptor (FCGR2A). Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Involved in EGF signaling pathway. Upon stimulation by EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3. Plays a negative role in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity. Down-regulates Fc-gamma-R-mediated phagocytosis in macrophages independently of INPP5D/SHIP1. In macrophages, down-regulates NF-kappa-B-dependent gene transcription by regulating macrophage colony-stimulating factor (M-CSF)-induced signaling. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6.
    • Tissue specificity
      Widely expressed, most prominently in skeletal muscle, heart and brain. Present in platelets. Expressed in transformed myeloid cells and in primary macrophages, but not in peripheral blood monocytes.
    • Involvement in disease
      Defects in INPPL1 may be a cause of susceptibility to type 2 diabetes mellitus non-insulin dependent (NIDDM) [MIM:125853].
      Note=Genetic variations in INPPL1 may be a cause of susceptibility to metabolic syndrome. Metabolic syndrome is characterized by diabetes, insulin resistance, hypertension, and hypertriglyceridemia is absent.
    • Sequence similarities
      Belongs to the inositol 1,4,5-trisphosphate 5-phosphatase family.
      Contains 1 SAM (sterile alpha motif) domain.
      Contains 1 SH2 domain.
    • Domain
      The SH2 domain interacts with tyrosine phosphorylated forms of proteins such as SHC1 or FCGR2A. It also mediates the interaction with p130Cas/BCAR1.
      The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain.
    • Post-translational
      Tyrosine phosphorylated by the members of the SRC family after exposure to a diverse array of extracellular stimuli such as insulin, growth factors such as EGF or PDGF, chemokines, integrin ligands and hypertonic and oxidative stress. May be phosphorylated upon IgG receptor FCGR2B-binding. Phosphorylated at Tyr-986 following cell attachment and spreading. Phosphorylated at Tyr-1162 following EGF signaling pathway stimulation. Phosphorylated at Thr-958 in response to PDGF.
    • Cellular localization
      Cytoplasm > cytosol. Cytoplasm > cytoskeleton > actin patch. Membrane. Translocates to membrane ruffles when activated, translocation is probably due to different mechanisms depending on the stimulus and cell type. Partly translocated via its SH2 domain which mediates interaction with tyrosine phosphorylated receptors such as the FC-gamma-RIIB receptor (FCGR2B). Tyrosine phosphorylation may also participate in membrane localization. Insulin specifically stimulates its redistribution from the cytosol to the plasma membrane. Recruited to the membrane following M-CSF stimulation.
    • Information by UniProt
    • Database links
    • Alternative names
      • 4 antibody
      • 5-trisphosphate 5-phosphatase 2 antibody
      • 51C protein antibody
      • EC 3.1.3.n1 antibody
      • inositol polyphosphate phosphatase like 1 antibody
      • Inositol polyphosphate phosphatase like protein 1 antibody
      • Inositol polyphosphate phosphatase-like protein 1 antibody
      • INPPL-1 antibody
      • INPPL1 antibody
      • OPSMD antibody
      • Phosphatidylinositol 3 antibody
      • Phosphatidylinositol 3,4,5 trisphosphate 5 phosphatase 2 antibody
      • Protein 51C antibody
      • SH2 domain containing inositol 5' phosphatase 2 antibody
      • SH2 domain-containing inositol 5''-phosphatase 2 antibody
      • SH2 domain-containing inositol phosphatase 2 antibody
      • SHIP-2 antibody
      • SHIP2 antibody
      • SHIP2_HUMAN antibody
      see all


    • Lane 1: Wild-type HAP1 whole cell lysate (20 µg)
      Lane 2: INPPL1 / SHIP-2 knockout HAP1 whole cell lysate (20 µg)
      Lane 3: HeLa whole cell lysate (20 µg)
      Lane 4: K562 whole cell lysate (20 µg)

      Lanes 1 - 4: Merged signal (red and green). Green - ab166916 observed at 139 kDa. Red - loading control, ab9484, observed at 37 kDa.

      ab166916 was shown to specifically react with INPPL1 / SHIP-2 in wild-type HAP1 cells. No band was observed when INPPL1 / SHIP-2 knockout samples were examined. Wild-type and INPPL1 / SHIP-2 knockout samples were subjected to SDS-PAGE. Ab166916 and ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

    • Immunohistochemical analysis of paraffin-embedded Human heart tissue labeling INPPL1 / SHIP-2 with ab166916 at 1/100 dilution.

    • All lanes : Anti-INPPL1 / SHIP-2 antibody [EPR10955] (ab166916) at 1/1000 dilution

      Lane 1 : K562 cell lysate
      Lane 2 : HeLa cell lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 139 kDa

    • Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling INPPL1 / SHIP-2 with ab166916 at 1/100 dilution.

    • Immunofluorescent analysis of HeLa cells labeling INPPL1 / SHIP-2 with ab166916 at 1/100 dilution.


    ab166916 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab166916.
    Please use the links above to contact us or submit feedback about this product.


    Sign up